GlobeNewswire by notified

Ad hoc announcement - GAM Holding AG releases interim statement for the three-month period to 31 March 2022


20 April 2022


Ad hoc announcement pursuant to Art. 53 listing rules:

GAM Holding AG releases interim statement for the three-month period to 31March 2022

Financial highlights

  • Investment ManagementAuMatCHF 30.0billion,with net client outflows of
    CHF 270millionand net negativemarket and foreign exchange(FX)movements of CHF 1.6billion
  • Fund Management ServicesAuMat CHF 64.8 billion,with net client inflows of CHF 290million, offset by net negative market and FXmovements of CHF 3.5billion
  • Investment performance: 73%of assets under management outperforming theirbenchmark over 3years as at 31 March2022, compared to 68% as at 31 December2021

Strategic highlights during first quarter 2022

  • Continued progress of GAM’s growth strategy reflected by overall net positive client inflows in the quarter
  • Launched strategic partnership with Liberty Street Advisors to provide clients with access to late-stage privately owned technology and innovation-driven companies and a low carbon infrastructure strategy
  • New Head of Investments, David Dowsett joined GAM
  • GAM achieved a ‘best in class’ rank in 4 out of 15 factors in Citywire European Fund Selector survey and top rated for accessibility of fund managers amongst 50 asset managers
  • GAM funds won several Refinitiv Lipper awards in Austria, France, Germany, Switzerland, the UK and for Europe overall
  • Financial Conduct Authoritypublication of final notice relating to the settlement previously announced in December, bringingthese matters to a close
  • Returned over 100% of the value of the GAM Greensill Supply Chain Finance Fund to clients marking the end of our legacy business relationship with Greensill

Peter Sanderson, Group CEO, said: “This has been an encouraging first quarter for GAM with net positive inflows for the firm overall. I am pleased that, despite pressure on the level of assets under management in the current market environment, our Investment Management business continues to improve with net inflows across a range of strategies and reduced outflows from our larger fixed income strategies.”  

Assets under Management

As at 31 March 2022, Group AuM totalled CHF 94.8 billion down from CHF 100.0 billion as at the end of December 2021.


AuM totalled CHF 30.0 billion, down from CHF 31.9 billion as at 31 December 2021, with net client outflows of CHF 270 million, and net negative market and foreign exchange movements of CHF 1.6 billion.

Net flows by capability

In fixed income, we recorded net outflows of CHF 396 million, primarily driven by outflows in the GAM Star Credit Opportunities and Local Emerging Bond funds, offset by inflows into GAM Star Cat Bonds and GAM Star MBS funds.

In equities, we saw another positive quarter with net inflows of CHF 28 million. While inflows were driven by a variety of funds, the main contributors were our GAM Star Continental European Equity and GAM Emerging Markets funds.

In multi asset, systematic and alternatives, we saw net inflows CHF 44 million, CHF16 million and CHF 67 million respectively.

Assets under management movements (CHF bn)

Capability Opening AuM
31 Dec 2021
Net client
Closing AuM
31 Mar 2022
Fixed Income 14.1 (0.40) (0.46) 13.2
Equity 8.0 0.03 (1.08) 7.0
Multi asset 7.7 0.04 (0.20) 7.5
Systematic 1.2 0.02 0.08 1.3
Alternatives 0.4 0.07 0.03 0.5
Absolute Return 0.5 (0.03) 0.00 0.5

Investment performance

Over the three-year period to 31 March 2022, 73% of AuM in investment management outperformed their benchmarks compared to 68% as at the end of December 2021. Over the five-year period to 31 March 2022, 51% of funds outperformed their benchmarks, down from 60% as at 31 December 2021. With respect to GAM’s AuM tracked by Morningstar 56% and 71% outperformed their peer groups over the three- and five-year periods as at 31 March 2022, respectively, compared to 70% and 62%, respectively, as at 31 December 2021.

Fund Management Services

Our Fund Management Services business reported AuM of CHF 64.8 billion, as at 31 March 2022, compared to CHF 68.0 billion as at 31 December 2021.

Assets under management movements (CHF bn)

Fund domicile Opening AuM
31 Dec 2021
Net flows Market/FX
Closing AuM
31 Mar 2022
Switzerland 14.4                      0.16 (0.31) 14.3
Rest of Europe 53.6 0.13 (3.21) 50.5
Total68.00.29(3.52)                 64.8

On 30 March 2022, a Fund Management Services client announced their intention to insource their funds to their own management company from April 2023. As at 31 December 2021, the relevant assets under management were CHF 11.5 billion with associated revenues of approximately CHF 6 million per annum. The client will be moving approximately CHF 10.5 billion of funds and approximately CHF 1.0 billion will remain with GAM.


We expect the market environment to remain challenging, with continuing geopolitical uncertainty, further increases in interest rates and a medium-term low growth outlook. However, we are encouraged by our improved momentum so far in 2022 and believe that clients will continue to be attracted by our distinctive range of investment products and fund solutions, which can help them address their investment needs in this challenging environment.

Upcoming events:

28April 2022         Annual General Meeting
3 August 2022       Half-year results 2022
20 October 2022    Q3 2022 Interim management statement

For further information please contact:

Charles Naylor         
Head of Communications and Investor Relations
T +44 7890 386 699

Investor Relations        Media Relations                
Stephen Gardner         Ute Dehn Christen        
T +44 7790 778544      T +41 58 426 31 36        

Visit us:
Follow us: Twitter and LinkedIn

About GAM

GAM is a leading independent, pure-play asset manager. The company provides active investment solutions and products for institutions, financial intermediaries, and private investors through three businesses: Investment Management, Fund Management Services and Wealth Management. GAM employed 605 FTEs in 14 countries with investment centres in London, Cambridge, Zurich, Hong Kong, New York, Milan, and Lugano as at 31 December 2021. The investment managers are supported by an extensive global distribution network. Headquartered in Zurich, GAM is listed on the SIX Swiss Exchange with the symbol ‘GAM’. The Group has AuM of CHF 94.8 billion (USD 103 billion) as at 31 March 2022.

Disclaimer regarding forward-looking statements

This press release by GAM Holding AG (‘the Company’) includes forward-looking statements that reflect the Company’s intentions, beliefs or current expectations and projections about the Company’s future results of operations, financial condition, liquidity, performance, prospects, strategies, opportunities, and the industry in which it operates. Forward-looking statements involve all matters that are not historical facts. The Company has tried to identify those forward-looking statements by using words such as ‘may’, ‘will’, ‘would’, ‘should’, ‘expect’, ‘intend’, ‘estimate’, ‘anticipate’, ‘project’, ‘believe’, ‘seek’, ‘plan’, ‘predict’, ‘continue’ and similar expressions. Such statements are made on the basis of assumptions and expectations which, although the Company believes them to be reasonable at this time, may prove to be erroneous.

These forward-looking statements are subject to risks, uncertainties, assumptions and other factors that could cause the Company’s actual results of operations, financial condition, liquidity, performance, prospects or opportunities, as well as those of the markets it serves or intends to serve, to differ materially from those expressed in, or suggested by, these forward-looking statements. Important factors that could cause those differences include but are not limited to changing business or other market conditions, legislative, fiscal, and regulatory developments, general economic conditions, and the Company’s ability to respond to trends in the financial services industry. Additional factors could cause actual results, performance, or achievements to differ materially. The Company expressly disclaims any obligation or undertaking to release any update of, or revisions to, any forward-looking statements in this press release and any change in the Company’s expectations or any change in events, conditions, or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.


To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified


AuctionAuction resultsAuction date2022-05-24Maturity2025Tendered volume, SEK mln500 +/- 500Offered volume, SEK mln994Volume bought, SEK mln0Number of bids4Number of accepted bids0 QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln34450000Volume bought, SEK mln0000Number of bids2100Number of accepted bids0000Average yield, %----Lowest accepted yield, %----Highest yield, %----Accepted at lowest yield, %---- QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln150000Volume bought, SEK mln0000Number of bids1000Number of accepted bids0000Average yield, %----Lowest accepted yield, %----Highest yield, %----Accepted at lowest yield, %----

Nexstim Receives an Order for Two NBS Systems from a Finnish University Hospital24.5.2022 11:30:00 CEST | Press release

Press release, Helsinki, 24 May 2022 at 12:30 PM (EEST) Nexstim Receives an Order for Two NBS Systems from a Finnish University Hospital Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") has received an order for two NBS 5 systems from a university hospital in Finland. The customer is an experienced user of the Nexstim NBS 4 system, now acquiring the two new systems to replace the old system and to increase capacity. Nexstim’s NBS (Navigated Brain Stimulation) system is used, for example, in planning neurosurgery or radiation therapy after a patient has had a diagnosis of a brain tumor or other disorder. When the lesion is predicted to be close to functional areas of the brain—such as those responsible for speech production and limb movement —the brain maps generated with NBS can be invaluable when deciding the best, personalized treatment option for the patient. These specific NBS systems also include the software of an NBT® (Navigated Brain Therapy) system, allowing the sys

Sweegen Wins Stevia Reb M Patent Lawsuit Against PureCircle24.5.2022 11:04:00 CEST | Press release

Rancho Santa Margarita, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- Sweegen, the global pioneer in wellness ingredient technologies and innovations, announced its victory against PureCircle in a stevia Rebaudioside M (Reb M) patent lawsuit. "Today's judgment vindicates Sweegen and affirms the company's position as an industry leader in innovative sweetener solutions," said Steven Chen, CEO of Sweegen. PureCircle, acquired by Ingredion in 2020, had filed the 2018 lawsuit against Sweegen in the U.S. District Court for the Central District of California, accusing Sweegen of infringing two PureCircle patents covering the manufacture of Reb M. The legal tide turned on PureCircle when Sweegen obtained a summary judgment that both of PureCircle's asserted patents are invalid. Since it is impossible to infringe an invalid patent, the court's invalidation of the asserted patents ends the infringement case against Sweegen at the U.S. District Court. "As a holder of core proprietary technologies of

Notification and Public Disclosure of Transactions by Person Discharging Managerial Responsibilities24.5.2022 11:00:00 CEST | Press release

Company Announcement No. 38/2022 Copenhagen, 24 May 2022 Notification and Public Disclosure of Transactions by Person Discharging Managerial Responsibilities 1. Information on the person discharging managerial responsibilities/person closely associated a) Name Anders Obel 2. Reason for the notification a) Position/title Member of the Board of Directors b) Initial notification/amendment Initial notification 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Scandinavian Tobacco Group A/S b) LEI code 5299003KG4JS99TRML67 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the financial instrument, type of instrument Identification code Shares DK0060696300 – STG b) Nature of the transaction Sale of shares c) Price(s) and volume(s) Price(s)Volume(s)DKK 147.6 7,

Disclosure of voting rights for Chairman of the Board24.5.2022 10:44:47 CEST | Press release

Oslo, 24 May 2022. PCI Biotech Holding ASA ("PCI Biotech" or the "Company") issue this notification on behalf of its chairman, Hans Peter Bøhn. Hans Peter Bøhn is chairman of PCI Biotech and shall open the annual general meeting of the Company on 25 May 2022. Mr. Bøhn holds 123,662 shares, representing 0.3 per cent of the share capital of PCI Biotech. Mr. Bøhn has received powers of attorney to represent and vote for 7,234,249 additional shares. In total, Mr. Bøhn will represent and vote for 19.7 per cent of the share capital. A major part of the powers of attorney are without voting instructions. The powers of attorney are only valid at the annual general meeting on 25 May 2022. This information is subject to the disclosure requirements pursuant to section 4 -3, cf. section 5-12 of the Norwegian Securities Trading Act. Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo Ronny Skuggedal, CFO,, Mobile: +47 9400 5757